Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_assertion type Assertion NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_head.
- NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_assertion description "[In this report, we explore the impact of the p38 activating, FDA-approved, blood brain barrier permeating compound celecoxib on SMN levels in vitro and in a mouse model of SMA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_provenance.
- NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_assertion evidence source_evidence_literature NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_provenance.
- NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_assertion SIO_000772 23656793 NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_provenance.
- NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_assertion wasDerivedFrom befree-20140225 NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_provenance.
- NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_assertion wasGeneratedBy ECO_0000203 NP752337.RAw9CdEu_rX0LhpauYXjKunFUMXLXOd-LZxUtNwcjwb_0130_provenance.